Colivelin
Colivelin is a brain-penetrant neuroprotective peptide, exhibiting potent long-term capacity against Aβ deposition, synaptic plasticity deficits, and neuronal apoptosis in neurodegenerative disease. Moreover, Colivelin is an activator of STAT3, which can rescue ischemic neuronal death and axonal remodeling by activating JAK/STAT3 signaling. Thus, Colivelin has the potential for the treatment of Alzheimer’s disease and ischemic brain injury.
References:
1. Zhao H, Feng Y, Wei C, et al. Colivelin Rescues Ischemic Neuron and Axons Involving JAK/STAT3 Signaling Pathway. Neuroscience, 2019, 416: 198-206.
2. Chiba T, Yamada M, Hashimoto Y, et al. Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo. The Journal of Neuroscience, 2005, 25(44): 10252-10261.
| Physical Appearance | White lyophilised solid |
| Storage | Store at -20°C |
| M.Wt | 2645.13 |
| Cas No. | 867021-83-8 |
| Formula | C119H206N32O35 |
| Solubility | insoluble in DMSO; insoluble in EtOH; ≥15 mg/mL in H2O |
| SDF | Download SDF |
| Canonical SMILES | CC[C@]([C@@](/N=C(O)/[C@](/N=C(O)/C/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/C/N=C(O)/[C@](/N=C(O)/[C@]1([H])CCCN1C([C@](/N=C(O)/[C@]2([H])CCCN2C([C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/ |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment:[2] | |
|
Cell lines |
Mouse primary cortical neurons (PCNs) |
|
Reaction Conditions |
100 aM, 1 fM, 10 fM, 100 fM, 1 pM, 10 pM, 100 pM, 1 nM, 10 nM, or 100 nM Colivelin for 16 h incubation |
|
Applications |
Colivelin at a concentration of 100 fM completely suppressed neuronal death induced by Aβ1-43. Colivelin was a femtomolar-acting bioactive peptide at least as potent as ADNF in vitro. Furthermore, Colivelin did not lose its neuroprotective activity even at higher concentrations. |
| Animal experiment:[1] | |
|
Animal models |
Male C57BL/6 mice, 10 ~ 12 wk of age |
|
Dosage form |
1 mg/kg Once daily by intraperitoneal injection for 6 days |
|
Applications |
Colivelin treatment resulted in improved motor and cognitive function over time (from day 1 to day 14 post ischemia and reperfusion), as shown by performance of mNSS, rotarod, and corner turning test. It also reduced lesion volume and improved neurological deficits after middle cerebral artery occlusion. |
|
Note |
The technical data provided above is for reference only. |
|
References: 1. Zhao H, Feng Y, Wei C, et al. Colivelin Rescues Ischemic Neuron and Axons Involving JAK/STAT3 Signaling Pathway. Neuroscience, 2019, 416: 198-206. 2. Chiba T, Yamada M, Hashimoto Y, et al. Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo. The Journal of Neuroscience, 2005, 25(44): 10252-10261. |
|
Quality Control & MSDS
- View current batch:
Chemical structure
